Phospho-Syntaxin 17 (Ser202) Antibody #28630
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Transfected Only |
| MW (kDa) | 40-42 |
| SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic phospho-peptide corresponding to residues surrounding Ser202 of human syntaxin 17 protein. Antibodies were purified by peptide affinity chromatography.
Background
Autophagy is a catabolic process for the autophagosomic-lysosomal degradation of bulk cytoplasmic contents (1,2). Autophagy is generally activated by conditions of nutrient deprivation but has also been associated with a number of physiological processes, including development, differentiation, neurodegeneration, infection, and cancer (3). Syntaxin 17/STX17 is a SNARE factor recruited to autophagosomes and required for autophagosome fusion to lysosomes. Syntaxin 17 interacts with SNAP29 (Qbc-SNARE synaptosome-associated protein 29) and the lysosomal factor VAMP8 (R-SNARE vesicle-associated membrane protein 8), as well as BRUCE, an inhibitor of apoptosis (IAP) protein, which is also involved in autophagosome/lysosome fusion (4,5).Syntaxin 17 promotes initiation of PINK1/Parkin-independent mitophagy, which is regulated by depletion of the mitochondrial outer membrane protein Fis1 (6).
Phosphorylation of Syntaxin 17 at Ser202 by TBK1 promotes the formation of the mammalian pre-autophagosomal structure (mPAS) and interaction with core components Atg13 and FIP200.
- Reggiori, F. and Klionsky, D.J. (2002) Eukaryot Cell 1, 11-21.
- Codogno, P. and Meijer, A.J. (2005) Cell Death Differ 12 Suppl 2, 1509-18.
- Levine, B. and Yuan, J. (2005) J Clin Invest 115, 2679-88.
- Viret, C. and Faure, M. (2019) Trends Cell Biol 29, 1-3.
- Corona, A.K. and Jackson, W.T. (2018) Trends Cell Biol 28, 869-81.
- Xian, H. et al. (2019) Nat Commun 10, 2059.
- Kumar, S. et al. (2019) Dev Cell 49, 130-144.e6.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.